Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis

Inclusion Criteria: * Male or female subjects who have reached age of majority * Willing to learn and able to self-administer study drug * Diagnosis of UC established at least 6 months before screening visit, by clinical and endoscopic evidence. * Currently experiencing moderate to severe active UC defined as a Mayo score of 6-12 (inclusive) at Screening. * Endoscopic evidence of active mucosal disease, as assessed by flexible sigmoidoscopy, with an Endoscopic Finding Sub-score of ≥2 at Screening. * Rectal Bleeding Sub-score of ≥1 at Screening. * Physician's Global Assessment Sub-score of ≥2 at Screening. * Male/female subjects who agree to practice effective methods of contraception Exclusion Criteria: * History of colonic or rectal surgery other than hemorrhoid surgery or appendectomy * Currently receiving total parenteral nutrition * Disease limited to ulcerative proctitis * Diagnosed with Crohn's disease, indeterminate colitis, microscopic colitis or, ischemic or infectious colitis * Known or suspected hypersensitivity to any component of the product * Known human immunodeficiency virus (HIV) infection or other immunosuppressive disorder * Concurrently participating in another study or receiving other experimental or investigational therapies within past 3 months * Females who are currently pregnant or lactating * Any history of malignancy. Exceptions may apply for cervical cancer and some forms of skin cancer